

## REMARKS

### *Claim Rejections under 35 U.S.C. § 112, First Paragraph*

Claims 34 and 35 are rejected under 35 U.S.C. § 112, first paragraph as failing to comply with the enablement requirement. This rejection is respectfully traversed and reconsideration thereof is respectfully requested.

Applicants respectfully submit that the specification is indeed enabling for claims 34 and 35. Specifically, Applicants respectfully point out that the last paragraph of page 6 of the application as filed provides the necessary guidance regarding how to use the invention as claimed in claims 34 and 35. That paragraph of page 6 recites the following:


“Further, as is well known in the art, treatment using the methods of the invention can be carried out in conjunction with the administration of antiemetics, which are drugs that are used to reduce nausea and vomiting that are common side effects of cancer chemotherapy. Examples of such drugs include major tranquilizers (e.g., phenothiazines, such as chlorpromazine and prochlorperazine), dopamine antagonists (e.g., metoclopramide), serotonin antagonists (e.g., ondansetron and granisetron), cannabinoids (e.g., dronabinol), and benzodiazepine derivatives.”

Accordingly, Applicants respectfully request that the Examiner withdraw her rejection of claims 34 and 35 under 35 U.S.C. § 112, first paragraph.

No new matter has been added.

Applicants respectfully submit the above arguments and respectfully request that the Examiner acknowledge patentability of pending claims 34 and 35. Applicants invite the Examiner to call their agent, Andrea L. C. Robidoux at (617) 248-5124, with any questions pertaining to the above-identified application in order to expedite prosecution of this case.

Respectfully submitted,



---

Andrea L. C. Robidoux, Reg. No. 47,902  
Agent for Applicants

CHOATE, HALL & STEWART  
PATENT GROUP  
Two International Place  
Boston, MA 02110  
(617) 248-5000  
Dated: **November 18, 2005**